Risk of Malignancy with the Use of Radioactive Iodine (131I) for Thyroid Disease
Risks of Malignancy Associated with Radioactive Iodide (I-131) Therapy for Thyroid Diseases
Saturday, May 9, 2020
11:30 AM – 12:30 PM
Participants should be aware of the following financial/non-financial relationships: Mark Tulchinsky, MD, FACNM, FSNMMI, CCD: Disclosure information not submitted. Sun Lee, MD, MSc, ECNU: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Identify the facts about 131I-associated secondary cancer risks.
Discuss key elements of discussing cancer risks vs. treatment benefits for 131I treatment.
Discuss key facts about cancer risks vs. treatment benefits for alternative treatments.